Add Presentation to Slide Tray Presentation:
First- and Second-Generation Antipsychotics for Children and Young Adults
Authors: John H. Coverdale, MD, MEd
Conclusions About the Benefits and Adverse Effects of Antipsychotics (1 of 2)
- Evidence about the use of antipsychotics in children and adolescents is inadequate to support strong conclusions about their comparative effectiveness.
- Moderate-strength evidence indicates that second-generation antipsychotics (SGAs) as a class improve clinical global impressions in bipolar disorder, and low-strength evidence supports benefits for treating mania.
- Moderate-strength evidence shows that SGAs as a class improve both clinical global impressions and positive and negative symptoms of schizophrenia.
- Moderate-strength evidence shows that risperidone is effective for attention deficit hyperactivity disorder and disruptive behavior disorders, and that risperidone and ziprasidone can reduce tics in Tourette’s syndrome.
- Limited evidence suggests that SGAs are more effective than first-generation antipsychotics for improving some autistic symptoms of pervasive developmental disorders.
- Seida J, Schouten J, Mousavi S, et al. First- and Second-Generation Antipsychotics for Children and Young Adults. Comparative Effectiveness Review No. 39 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021). Rockville, MD: Agency for Healthcare Research and Quality; February 2012. AHRQ Publication No. 11(12)-EHC077-EF. Available at www.effectivehealthcare.ahrq.gov/pedantipsych.cfm.
Your slide tray is being processed.